ABUS Insider Trading Activity and SEC Form 4 Filings
ABUS insider trading summary
No open-market insider purchases or sales of Arbutus Biopharma Corp (ABUS) have been reported on SEC Form 4 in the past 12 months.
Latest ABUS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 4, 2025 | J. Christopher Naftzger | General Counsel and CCO | Sell | $37K (11,333 @ $3.28) |
| Feb 4, 2025 | Karen Sims | Chief Medical Officer | Sell | $64K (19,348 @ $3.28) |
| Feb 4, 2025 | Michael J. McElhaugh | Interim President & CEO | Sell | $78K (23,790 @ $3.28) |
| Feb 4, 2025 | David C Hastings | Chief Financial Officer | Sell | $73K (22,183 @ $3.28) |
| Aug 14, 2024 | Keith S Manchester | Director | Sell | $33K (8,846 @ $3.69) |
| Feb 2, 2024 | Karen Sims | Chief Medical Officer | Sell | $10K (4,358 @ $2.31) |
| Feb 2, 2024 | Michael J. McElhaugh | Interim President & CEO | Sell | $24K (10,164 @ $2.31) |
| Feb 2, 2024 | Michael J. Sofia | Chief Scientific Officer | Sell | $23K (9,982 @ $2.31) |
| Feb 2, 2024 | David C Hastings | Chief Financial Officer | Sell | $22K (9,593 @ $2.31) |
| Dec 1, 2021 | Michael J. Sofia | Chief Scientific Officer | Sell | $1.0M (200,000 @ $5.09) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.